

Clinical Trial Protocol

Iranian Registry of Clinical Trials

13 Jul 2026

Investigation and comparison of the efficacy and side effects of only nebulized oral Pulmicort and only inhaled budesonide and diet with oral budesonide nebul in patients aged one to 18 years with eosinophilic esophagitis

Protocol summary

Study aim

Comparison of eosinophilia and clinical symptoms improvement in children with eosinophilic esophagitis in three groups: oral budesonide nebulization intervention, inhaled budesonide spray and non-drug diet regimen, and follow-up of local and systemic side effects.

Design

A randomized, double blinded clinical trial study with community-based and pragmatic control group, and parallel groups

Settings and conduct

After patient's selection based on inclusion and exclusion criteria, the basic results of endoscopic, histopathological examination, eosinophil count, as well as routine hematological and biochemical tests will be measured. Patients will be randomly divided into three intervention groups of nebulized oral pulmicort, inhaler budesonide and diet without drug. At the beginning of the study and after the end of week 16th, patients in all groups will be referred again to the center for endoscopy by a specialist physician and will be examined histologically and histologically, as well as eosinophil counts and cortisol examination at 8 am o'clock.

Participants/Inclusion and exclusion criteria

Only patients 1 to 18 years of age with eosinophilic esophagitis will be included in the study. Children with a history of systemic disease, adrenal insufficiency, other congenital or genetic defects, and a history of systemic corticosteroid medications will be excluded from the study.

Intervention groups

only oral budesonide nebul group only inhaled budesonide spray group mixed food elimination plus oral nebul

Main outcome variables

The important outcome of the current survey is the

effect of nebulized oral pulmicort, inhaler budesonide and diet without drug for improving of eosinophilic esophagitis which is performed by measuring several factors such as eosinophil counts, as well as endoscopic and histopathological examinations.

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191211045703N1**

Registration date: **2020-06-24, 1399/04/04**

Registration timing: **registered_while_recruiting**

Last update: **2020-06-24, 1399/04/04**

Update count: **0**

Registration date

2020-06-24, 1399/04/04

Registrant information

Name

Nastaran Amiri

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 2222 2041

Email address

drnastaranamiri@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-02-04, 1398/11/15

Expected recruitment end date

2020-09-05, 1399/06/15

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigation and comparison of the efficacy and side effects of only nebulized oral Pulmicort and only inhaled budesonide and diet with oral budesonide nebul in patients aged one to 18 years with eosinophilic esophagitis

Public title

Comparison of the efficacy and side effects of nebulized oral pulmicort and inhaler budesonide in patients with eosinophilic esophagitis

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Pediatric patients with eosinophilic esophagitis consent form parents proton pump consumption Adherence to the treatment protocols of this study

Exclusion criteria:

history of systemic corticosteroids drugs using history of systemic underlying diseases Adrenal insufficiency history

Age

From **1 year** old to **18 years** old

Gender

Both

Phase

N/A

Groups that have been masked

- Data analyser

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

For this purpose, the random allocation law method was used. In random allocation (based on probability principles) eliminates the link between intervention and potential distortion. Random allocation was used by variable block method. The randomization unit was individual. In this way, a set of 60 cards was prepared, which included three 20-block blocks of three types of cards A, B, and C, which were randomly and randomly removed for each person by the researcher. The collection could not be returned.

Blinding (investigator's opinion)

Double blinded

Blinding description

Due to the fact that this study did not have a placebo and the drug form used was completely different. Only the data analyst did not know which group the recorded clinical information belonged to.

Placebo

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Iran University of Medical Sciences

Street address

Zafar Street, Ali Asghar Hospital

City

tehran

Province

Tehran

Postal code

1919816366

Approval date

2019-11-26, 1398/09/05

Ethics committee reference number

IR.IUMS.FMD.REC.1398.371

Health conditions studied**1****Description of health condition studied**

eosinophilic esophagitis

ICD-10 code

K20.0

ICD-10 code description

Eosinophilic esophagitis

Primary outcomes**1****Description**

The effect of oral Budesonide nebulizer on improving Eosinophilic Esophagitis.

Timepoint

Patients in the oral Budesonide nebulizer group will receive 1 puff twice a day. If the effectiveness of the drug is not observed after 8 weeks, patients will receive 2 puffs twice a day. Then during weeks 4, 12, 8 and 16 patients will be followed up and examined.

Method of measurement

At the beginning of the study and after the 16th week, patients will be re-examined for histological and tissue pathology, as well as blood eosinophil counts and cortisol examination by Enzyme-linked immunosorbent test at 8 a.m. There will also be a routine laboratory test, such as hematology and biochemistry.

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: nebulized oral pulmicort. Palmicortic is a drug containing budesonide and belongs to the corticosteroids, which are commonly used to reduce and prevent inflammation and swelling in the lungs and asthma. The drug is manufactured by ASTRAZENECA from Sweden. Patients in pulmicort group less than 20 kg will receive 0.5 mg/dose/day, while those over 20 kg will receive 1 mg/dose/day for 8 weeks. In case there is no improvement in the disease after 8 weeks, patients fewer than 20 kg will receive 1mg/dose/day and those over 20 kg will receive 2 mg/dose/day. Patients will be followed-up on the 4th, 8th, 12th, and 16th weeks.

Category

Treatment - Drugs

2

Description

Intervention group: inhaler budesonide. An inhaled drug containing budesonide belongs to the corticosteroids, which are commonly used to reduce and prevent inflammation and swelling in the lungs and asthma. Each prescription contains 2 ml of sterile solution. This solution must be turned into steam for inhalation in a special device. Patients in the budesonide spray group will receive 1 puff twice daily. In case no efficacy is observed, patients will receive 2 puffs twice daily for 8 weeks. Patients will then be monitored and evaluated on 4th, 8th, 12th and 16th weeks.

Category

Treatment - Drugs

3

Description

Control group: diet without drug. In this group patients will not receive any type of drug intervention.

Category

Lifestyle

Recruitment centers

1

Recruitment center

Name of recruitment center

Hazrat-e Rasul Hospital

Full name of responsible person

Nastarn Amiri

Street address

Hazrate Rasool Akram Hospital, Niayesh St, Satarkhan Ave, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1445613131

Phone

+98 21 6651 5001

Fax

Email

Shahriary961@gmail.com

Web page address

<https://hrmc.iums.ac.ir/>

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Dr. Morteza Fallah pour

Street address

Ali Asghar Hospital, Zafar Street, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1919816766

Phone

+98 21 2222 2041

Fax

Email

drnastaranamiri@gmail.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Iran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Nastaran Amiri

Position

رئیس دند اطفال

Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Zafar street, Ali Asghar Hospital
City
Tehran
Province
Tehran
Postal code
1919816766
Phone
+98 21 2222 2041
Fax
Email
drnastaranamiri@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Nastaran Amiri
Position
رئیس دپارتمان اطفال
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
Zafar street, Ali Asghar Hospital
City
Tehran
Province
Tehran
Postal code
1919816766
Phone
+98 21 2222 2041
Fax
Email
drnastaranamiri@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Nastaran Amiri

Position
Pediatrics
Latest degree
Medical doctor
Other areas of specialty/work
Pediatrics
Street address
خیابان ظفر
City
tehran
Province
Tehran
Postal code
1919816766
Phone
+98 21 2222 2041
Email
drnastaranamiri@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
Yes - There is a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Yes - There is a plan to make this available
Data Dictionary
Yes - There is a plan to make this available
Title and more details about the data/document
Documents and information of demographic data, clinical and pathological findings of all patients will be shared, but personal data are will not be shared.
When the data will become available and for how long
At the end of study and after publication of article
To whom data/document is available
University researchers physicians pharmacologists
Under which criteria data/document could be used
Medical researcher can use data after getting admission from all members of this study for further research
From where data/document is obtainable
They should contact with Dr. Nastaran Amiri
What processes are involved for a request to access data/document
They should initially contact with Dr. Nastaran Amiri to get permission
Comments